End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.93 CNY | -1.75% | -1.00% | -10.77% |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The group's high margin levels account for strong profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.77% | 1.05B | - | ||
+32.81% | 5.82B | B- | ||
-25.27% | 3.97B | C+ | ||
+5.41% | 3.31B | C | ||
-21.39% | 2.76B | B- | ||
-11.93% | 2.26B | - | D+ | |
+44.07% | 1.92B | - | ||
-17.86% | 1.5B | - | - | |
+43.25% | 1.48B | - | ||
-9.38% | 1.49B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 002275 Stock
- Ratings Guilin Sanjin Pharmaceutical Co., Ltd.